Cirtuvivint
Tier C — Watch / tradeCirtuvivint
Targets：CLK, DYRK kinase
Indications (approved)：Small cell lung cancer, Soft tissue neoplasm, Peritoneal cancer, Fallopian tube cancer, Myelodysplastic syndrome, Acute myeloid leukaemia, Non-small cell lung cancer, Colorectal cancer
Regional status
Synthetic routes & intermediates
Frequently asked questions
What are the approved indications of Cirtuvivint?
Approved indications include: Small cell lung cancer, Soft tissue neoplasm, Peritoneal cancer, Fallopian tube cancer, Myelodysplastic syndrome, Acute myeloid leukaemia, Non-small cell lung cancer, Colorectal cancer.
When does the Cirtuvivint patent expire?
No public expiry year is available for Cirtuvivint yet; this page updates once verified.
How do I get a quote for Cirtuvivint intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01